Provectus Biopharmaceuticals (STU:PXY) PB Ratio: (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PXY Provectus Biopharmaceuticals Inc STU:PXY
35 GF Score
Price €0.05
! 3 Warning Signs
View Full Analysis

What is Provectus Biopharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-04), Provectus Biopharmaceuticals's share price is €0.045. Provectus Biopharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2026 was €-0.01. Hence, Provectus Biopharmaceuticals's PB Ratio of today is .

The historical rank and industry rank for Provectus Biopharmaceuticals's PB Ratio or its related term are showing as below:

STU:PXY's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.765
* Ranked among companies with meaningful PB Ratio only.

During the past 5 years, the average Book Value Per Share Growth Rate was 17.90% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Provectus Biopharmaceuticals was 39.40% per year. The lowest was -41.20% per year. And the median was -20.35% per year.

Back to Basics: PB Ratio


Provectus Biopharmaceuticals  (STU:PXY) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Provectus Biopharmaceuticals PB Ratio Related Terms


Provectus Biopharmaceuticals PB Ratio Historical Data

* Premium members only.

The historical data trend for Provectus Biopharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Provectus Biopharmaceuticals PB Ratio Chart

Provectus Biopharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Provectus Biopharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:PXY vs PSTV, ALGS, ATNM: PB Ratio Comparison

For the Biotechnology subindustry, Provectus Biopharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Provectus Biopharmaceuticals PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Provectus Biopharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Provectus Biopharmaceuticals's PB Ratio falls into.


STU:PXY
35GF Score
Provectus Biopharmaceuticals Inc STU:PXY
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Provectus Biopharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Provectus Biopharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=0.045/-0.014
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Provectus Biopharmaceuticals Business Description

Other Exchanges PVCT:USA
Address 800 South Gay Street, Suite 1610, Knoxville, TN, USA, 37929
Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of bioactive synthetic small molecule halogenated xanthenes (HXs). Its flagship HX molecule is named rose bengal sodium (RBS). The company's proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient (API) in all its clinical development and non-clinical research programs. It has one operating and reporting segment, namely, the development of immunotherapy medicines.
35GF Score

Get the complete analysis for STU:PXY

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.05
Price